Digestive Enzyme

Lactase enzyme

Beta-galactosidase (lactase)

Evidence TierAWADA NOT PROHIBITED

tuneTypical Dose

3000-9900+

watchEffect Window

Acute meal period (hours)

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Lactase enzyme helps digest lactose and reduce lactose-intolerance symptoms.

It has strong evidence for reducing gas, bloating, and hydrogen-breath responses when taken with lactose-containing meals. Match enzyme timing to lactose intake for best effect.

Direct enzymatic lactose breakdown reduces undigested lactose fermentation and associated symptoms.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Reduced lactose-related GI symptoms
  • Reduced hydrogen breath response to lactose challenge

Secondary Outcomes

  • Improved meal tolerance in lactose maldigesters
  • Dose-response based on lactose load

Safety

Contraindications and Interactions

Contraindications

  • Product-excipient allergy
  • Undiagnosed severe GI disease
  • Infant use without clinical guidance

Side effects

  • Usually minimal direct side effects
  • Residual symptoms if under-dosed
  • Rare intolerance to formulation excipients

Interactions

  • No major systemic drug interactions expected
  • Compatible with most GI-support regimens
  • Dose effect can be confounded by very high lactose loads

Avoid if

  • Persistent alarming GI symptoms without diagnosis
  • Known allergy to product ingredients
  • Unsupervised infant administration

Evidence

Study-level References

lactase-enzyme-SRC-001Randomized double-blind crossover placebo-controlled trial
Sourceopen_in_new

Baijal R, Tandon RK. Effect of lactase on symptoms and hydrogen breath levels in lactose intolerance: A crossover placebo-controlled study. JGH Open. 2021;5(1):143-148. doi:10.1002/jgh3.12463. PMID:33490624.

Population: Adults with lactose intolerance (n=47)

Dose protocol: Lactase tablets before lactose challenge

Key findings: Significant symptom and H2 reduction (about 55% cumulative H2 reduction)

Notes: Strong within-subject crossover design

Paper content

Significant symptom and H2 reduction (about 55% cumulative H2 reduction)

lactase-enzyme-SRC-002Randomized double-blind crossover trial
Sourceopen_in_new

Sanders SW, et al. Effect of a single dose of lactase on symptoms and expired hydrogen after lactose challenge in lactose-intolerant subjects. Clin Pharm. 1992;11(6):533-538. PMID:1534729.

Population: Lactose-intolerant adults (n=24 completers)

Dose protocol: 9900 FCC units single pre-challenge dose

Key findings: Lower hydrogen output and symptom severity

Notes: Older trial but clear challenge model

Paper content

Lower hydrogen output and symptom severity

lactase-enzyme-SRC-003Randomized comparative trial with placebo arm
Sourceopen_in_new

Ojetti V, et al. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose-intolerant patients: randomized trial. Eur Rev Med Pharmacol Sci. 2010;14(3):163-170. PMID:20391953.

Population: Lactose-intolerant adults (n=60)

Dose protocol: Tilactase pre-challenge vs placebo vs probiotic pretreatment

Key findings: Tilactase outperformed placebo and probiotic for acute outcomes

Notes: Mixed-comparator design

Paper content

Tilactase outperformed placebo and probiotic for acute outcomes

lactase-enzyme-SRC-004Randomized crossover trials
Sourceopen_in_new

Rasinkangas P, et al. Bifidobacterium animalis subsp. lactis Bi-07 supports lactose digestion in vitro and in randomized, placebo- and lactase-controlled trials. Am J Clin Nutr. 2022;116(6):1580-1594. doi:10.1093/ajcn/nqac264. PMID:36149331.

Population: Lactose-intolerant adults

Dose protocol: Probiotic vs 4662 FCC lactase vs placebo

Key findings: Lactase improved breath-hydrogen outcomes in trial context

Notes: Comparator context confirms lactase benchmark role

Paper content

Lactase improved breath-hydrogen outcomes in trial context

Guides

Setup

Help